PMID- 21427170
OWN - NLM
STAT- MEDLINE
DCOM- 20110818
LR  - 20211203
IS  - 1479-6821 (Electronic)
IS  - 1351-0088 (Linking)
VI  - 18
IP  - 3
DP  - 2011 Jun
TI  - mTOR inhibition, a potential novel approach for bronchial carcinoids.
PG  - C15-8
LID - 10.1530/ERC-10-0290 [doi]
AB  - Although targeted therapy, including inhibitors of mammalian target of rapamycin 
      (mTOR) and vascular endothelial growth factor, being developed for carcinoids 
      arised from the gastrointestinal tract, treatment for locally advanced or 
      metastatic bronchial carcinoids (BCs) remains lacking. Traditional cytotoxic 
      chemotherapy offers essentially minimal benefit to this largely 
      under-characterized tumor. In the September issue of Endocrine-Related Cancer, 
      Zatelli et al. reported an anti-proliferative effect of mTOR inhibitor, 
      everolimus, in cultured primary BC tumor cells by attenuation of IGF signaling 
      pathway. This effect is more significant in aggressive tumors that carry higher 
      levels of mTOR, and is consistent with the therapeutic benefit of everolimus for 
      patients with BC observed in our phase II and III clinical trials. Although 
      adding somatostatin analog to mTOR inhibitor did not provide a synergistic 
      anti-tumor effect, development of rational combinations is highly warranted to 
      further improve the outcome for patients with neuroendocrine tumors.
FAU - Dong, Mei
AU  - Dong M
AD  - Department of Gastrointestinal Medical Oncology, Unit 426, The University of 
      Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, 
      USA.
FAU - Yao, James C
AU  - Yao JC
LA  - eng
PT  - Journal Article
DEP - 20110428
PL  - England
TA  - Endocr Relat Cancer
JT  - Endocrine-related cancer
JID - 9436481
RN  - 0 (Antineoplastic Agents)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - Bronchial Neoplasms/*drug therapy
MH  - Carcinoid Tumor/*drug therapy
MH  - Disease-Free Survival
MH  - Everolimus
MH  - Humans
MH  - Molecular Targeted Therapy
MH  - Sirolimus/*analogs & derivatives/pharmacology/therapeutic use
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors
EDAT- 2011/03/24 06:00
MHDA- 2011/08/19 06:00
CRDT- 2011/03/24 06:00
PHST- 2011/03/24 06:00 [entrez]
PHST- 2011/03/24 06:00 [pubmed]
PHST- 2011/08/19 06:00 [medline]
AID - ERC-10-0290 [pii]
AID - 10.1530/ERC-10-0290 [doi]
PST - epublish
SO  - Endocr Relat Cancer. 2011 Apr 28;18(3):C15-8. doi: 10.1530/ERC-10-0290. Print 
      2011 Jun.